The Push to Subsidise GLP-1 Drugs for PMOS, Explained

An Australian advocacy group wants GLP-1 drugs subsidised on the PBS for people living with PMOS.

The Polyendocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is calling for formal, subsidised access for this patient group. That would shift PMOS use from private, off-label prescribing into the PBS framework. Off-label means prescribed for a condition regulators have not formally approved, and the PBS, the Pharmaceutical Benefits Scheme, is Australia's system for lowering the cost of listed medicines.

PMOS was formerly known as polycystic ovarian syndrome. It affects one in eight women. Australia's Therapeutic Goods Administration (TGA), which approves drugs for specific uses, has not specifically approved GLP-1 drugs to treat PMOS. Still, patients are being prescribed GLP-1 medications off-label for the condition, according to The Guardian.

The cost is private. GLP-1 medications can cost patients several hundred dollars each month. An estimated half a million Australians use weight-loss medications regularly, according to a UNSW study reported in July 2026. For weight loss without type 2 diabetes, access to GLP-1 receptor agonists in Australia is only available through private prescriptions.

PBS coverage remains narrow. Ozempic is listed on the PBS only for the treatment of diabetes. As of February 2026, two GLP-1 medicines were listed on the PBS for type 2 diabetes, including dulaglutide (Trulicity). Patients who previously received a PBS-subsidised prescription for a GLP-1 receptor agonist can access the medicine via streamlined listing, a simpler renewal path.

The Pharmaceutical Benefits Advisory Committee (PBAC), which advises government on subsidies, has recommended Wegovy be subsidised for people with a body mass index above 35. BMI is a height-weight measure used to define obesity thresholds. Both Ozempic and Wegovy are produced by Novo Nordisk and contain the same active ingredient, semaglutide, with Wegovy at a higher dose. The Committee has separately recommended a slow and managed rollout of access to PBS-subsidised GLP-1 treatments, a position outlined in March 2026. GLP-1 medicines are not subsidised through the PBS for the purpose of losing weight, and people who want to use them for weight loss must pay for the medicines.

The medical case cited in the literature focuses on metabolic and reproductive effects. The metabolic symptoms of PMOS, including overweight and diabetes, may be effectively treated by GLP-1s. Semaglutide has been described in the literature as an important tool for treatment of irregular menses and chronic anovulation, ongoing lack of ovulation, in women with Polyendocrine Metabolic Ovarian Syndrome. GLP-1 receptor agonists are reported to oppose the metabolic effect of PCOS, leading to decreased toxicity of endometrial tissue and improved implantation.

Lorna Berry is a spokesperson for POSAA. The Royal Australasian College of Physicians did not have a position on whether GLP-1s were appropriate for management of PMOS as of October 2026.

The broader context here is a familiar PBS sequencing problem, where clinical practice, regulatory approval and subsidy rules move at different speeds. Off-label prescribing allows early use but preserves the price barrier. A TGA indication specific to PMOS would clarify prescribing authority, while a PBS listing would address affordability. The PBAC recommendation on Wegovy for BMI above 35 suggests regulators are willing to consider weight-related subsidy, but through an obesity threshold rather than a syndrome-specific pathway.

Looking at what this means for access, the choice between those two pathways matters. A BMI criterion captures only a subset of people with PMOS and ties eligibility to body size rather than hormone disease. A PMOS-specific listing would tie eligibility to diagnosis, but would require evidence on efficacy, safety and cost-effectiveness in that population that satisfies PBAC and, for indication, the TGA. That evidentiary step is where advocacy typically meets its test.